Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), confirmed by tissue testing, who have either never received treatment or whose disease has come back or stopped responding to treatment.
• People who are starting their first treatment may have already received some emergency chemotherapy before joining, including one prior cycle of a BPDCN-directed therapy such as SL-401.
• People who have previously received or are currently receiving the drugs cytarabine (ARA-C) or hydroxyurea to control rapidly growing disease may still be considered.
• People whose disease has returned or stopped responding to treatment and who have completed at least one prior cycle of therapy.
• People aged 18 years or older.
• People with a general health and activity level rated as reasonably functional (this is measured on a standard medical scale — confirm with trial site what this means for a specific situation).
• People whose organs (including kidneys, liver, and protein levels in the blood) are working well enough to meet specific laboratory thresholds set by the trial (confirm with trial site for exact values).
• People who are willing and able to read and sign a consent form agreeing to take part.
• People who are able to attend all required study visits and follow-up appointments.
• Women who could become pregnant, and men enrolled in the trial, must agree to use effective contraception during the study and for 2 months after the last dose of the study drug; acceptable methods include birth control pills or injections, intrauterine devices (IUDs), or a double-barrier method such as a condom used with spermicide. Men must also agree not to donate sperm during the study and for at least 8 weeks after their last dose of SL-401.
• People whose heart is pumping effectively, confirmed by a heart scan (MUGA or echocardiogram) performed within 30 days before the first treatment.

Who may not be able to join:

• People who are pregnant or breastfeeding.
• People with a known active hepatitis B or hepatitis C infection, or who have tested positive for HIV.
• People who have had major surgery or radiation therapy within the 14 days before the first study treatment.
• People who have active or untreated disease affecting the membranes around the brain and spinal cord, or who have spinal cord compression causing symptoms.
• People with serious heart disease, including those with significant heart failure, or who have had unstable chest pain, a stroke, or a heart attack within the past 6 months.
• People who have difficulty absorbing medications through the digestive system or have other conditions that prevent taking medication by mouth.
• People with other serious ongoing medical, mental health, or laboratory conditions that the trial doctor believes could make participation unsafe or affect the reliability of the trial results.

Important: Always verify eligibility with the trial site directly before applying.